UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 51

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure

Journal of clinical oncology, 2010-10, Vol.28 (30), p.4568-4574

2010

Volltextzugriff (PDF)

Similarity of Bisphenol A Pharmacokinetics in Rhesus Monkeys and Mice: Relevance for Human Exposure

Environmental health perspectives, 2011-04, Vol.119 (4), p.422-430

2011

Volltextzugriff (PDF)

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients

PloS one, 2022-01, Vol.17 (1), p.e0256752-e0256752

2022

Volltextzugriff (PDF)

Intestinal secretion is a major route for parent ivermectin elimination in the rat

Drug metabolism and disposition, 2002-06, Vol.30 (6), p.626-630

2002

Volltextzugriff (PDF)

Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest

Frontiers in psychiatry, 2024-06, Vol.15, p.1399803

2024

Volltextzugriff (PDF)

Are population pharmacokinetic and/ or pharmacodynamic models adequately evaluated? : A survey of the literature from 2002 to 2004

Clinical pharmacokinetics, 2007-01, Vol.46 (3), p.221-234

2007

Volltextzugriff (PDF)

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder

Frontiers in pharmacology, 2022-11, Vol.13, p.1052113-1052113

2022

Volltextzugriff (PDF)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder

Harm reduction journal, 2023-12, Vol.20 (1), p.173-13, Article 173

2023

Volltextzugriff (PDF)

Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients

Pharmaceutical research, 2013-11, Vol.30 (11), p.2795-2807

2013

Volltextzugriff (PDF)

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection

Journal of pharmacokinetics and pharmacodynamics, 2017-04, Vol.44 (2), p.69-79

2017

Volltextzugriff (PDF)

Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs

American journal of veterinary research, 2014-02, Vol.75 (2), p.124-131

2014

Volltextzugriff (PDF)

Model-Based Approach to Early Predict Prolonged High Grade Neutropenia in Carboplatin-Treated Patients and Guide G-CSF Prophylactic Treatment

Pharmaceutical research, 2015-02, Vol.32 (2), p.654-664

2015

Volltextzugriff (PDF)

Modeling buprenorphine reduction of fentanyl-induced respiratory depression

JCI insight, 2022-05, Vol.7 (9)

2022

Volltextzugriff (PDF)

Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations

Journal of antimicrobial chemotherapy, 2011-08, Vol.66 (8), p.1798-1809

2011

Volltextzugriff (PDF)

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder

Drugs in R&D, 2019-09, Vol.19 (3), p.255-265

2019

Volltextzugriff (PDF)

Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model

The AAPS journal, 2011-09, Vol.13 (3), p.390-404

2011

Volltextzugriff (PDF)

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

Journal of pharmacokinetics and pharmacodynamics, 2009-08, Vol.36 (4), p.317-339

2009

Volltextzugriff (PDF)

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials

Clinical pharmacokinetics, 2021-04, Vol.60 (4), p.527-540

2021

Volltextzugriff (PDF)

Tolerance to Opioid‐Induced Respiratory Depression in Chronic High‐Dose Opioid Users: A Model‐Based Comparison With Opioid‐Naïve Individuals

Clinical pharmacology and therapeutics, 2021-03, Vol.109 (3), p.637-645

2021

Volltextzugriff (PDF)

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide

Pharmaceutical research, 2006-09, Vol.23 (9), p.2036-2049

2006

Volltextzugriff (PDF)

Licking behaviour and environmental contamination arising from pour-on ivermectin for cattle

International journal for parasitology, 2001-12, Vol.31 (14), p.1687-1692

2001

Volltextzugriff (PDF)

An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients

Clinical drug investigation, 2024-04, Vol.44 (4), p.251-260

2024

Volltextzugriff (PDF)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder

The international journal of neuropsychopharmacology, 2021-02, Vol.24 (2), p.89-96

2021

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder

Journal of clinical pharmacology, 2016-07, Vol.56 (7), p.806-815

2016

Volltextzugriff (PDF)

Exposure‐response analysis after subcutaneous administration of RBP‐7000, a once‐a‐month long‐acting Atrigel formulation of risperidone

British journal of clinical pharmacology, 2017-07, Vol.83 (7), p.1476-1498

2017

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(50)
Bücher
(1)

Sprache

Englisch
(48)
Französisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure

Similarity of Bisphenol A Pharmacokinetics in Rhesus Monkeys and Mice: Relevance for Human Exposure

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients

Intestinal secretion is a major route for parent ivermectin elimination in the rat

Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest

Are population pharmacokinetic and/ or pharmacodynamic models adequately evaluated? : A survey of the literature from 2002 to 2004

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder

Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection

Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs

Model-Based Approach to Early Predict Prolonged High Grade Neutropenia in Carboplatin-Treated Patients and Guide G-CSF Prophylactic Treatment

Modeling buprenorphine reduction of fentanyl-induced respiratory depression

Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder

Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials

Tolerance to Opioid‐Induced Respiratory Depression in Chronic High‐Dose Opioid Users: A Model‐Based Comparison With Opioid‐Naïve Individuals

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide

Licking behaviour and environmental contamination arising from pour-on ivermectin for cattle

An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder

Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder

Exposure‐response analysis after subcutaneous administration of RBP‐7000, a once‐a‐month long‐acting Atrigel formulation of risperidone

Suchergebnisse filtern